What Does the FDA Label Say About Reglan and Tardive Dyskinesia?
From General Health Awareness to Occupational Exposure Concerns
If you or a loved one has taken Reglan (metoclopramide) for a gastrointestinal condition, you may be concerned about the risk of tardive dyskinesia—a potentially irreversible movement disorder. This concern is backed by FDA label warnings that highlight the need for careful monitoring, especially with long-term use. Building on decades of pharmacovigilance research, this page explains the clinical red flags outlined in the FDA label and what they mean for patients and prescribers.
Reglan and Tardive Dyskinesia: Medical Evidence and Risk Context
Reglan (metoclopramide) is a medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The FDA-approved labeling includes a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling notes that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis because it may mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, total duration of treatment with metoclopramide products, including Reglan tablets, should be avoided for longer than 12 weeks; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan tablets are not recommended for use in pediatric patients due to the risk of developing TD and other extrapyramidal symptoms, as well as the risk of methemoglobinemia in neonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking Reglan to TD involves metoclopramide's dopamine D2 receptor antagonism in the basal ganglia, which can lead to supersensitivity of dopamine receptors and subsequent involuntary movements. The labeling advises avoiding concomitant use of other drugs known to cause TD, extrapyramidal symptoms, or neuroleptic malignant syndrome, and avoiding use in patients with Parkinson's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If symptoms of TD occur, Reglan should be immediately discontinued and medical attention sought (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Regarding the adequacy of warnings, the boxed warning explicitly states the risk of TD, the relationship to duration and dosage, and the contraindication in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling also includes warnings and precautions sections that detail TD, other extrapyramidal symptoms, and neuroleptic malignant syndrome (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Statute of Limitations for Reglan Claims in Massachusetts
Despite these warnings, cases of TD have occurred, and settlement-related considerations for affected patients often involve evaluating whether the prescribing physician or manufacturer provided adequate information about the risks and whether the duration of treatment exceeded recommended limits. For patients in Massachusetts, the statute of limitations for filing a Reglan TD lawsuit is typically governed by state law, which generally requires claims to be filed within a certain period from the date of injury or discovery of the injury. The timeline between exposure and documented harm is critical: TD may develop after months or years of metoclopramide use, and symptoms can appear after discontinuation. The labeling emphasizes using Reglan for the shortest duration and periodically reassessing the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Patients who developed TD after prolonged use beyond the recommended 12-week limit may have stronger claims, as the risk increases with longer exposure. Settlement-related considerations include the severity and irreversibility of TD, the extent of medical monitoring and treatment needed, and whether the patient was adequately warned. The FDA-approved labeling provides clear guidance on duration limits and monitoring, which may be used to assess whether standard of care was met. Patients should consult with legal counsel to understand the specific statute of limitations in Massachusetts, as it can vary based on the date of injury or discovery. In summary, Reglan carries a known risk of TD, with the risk increasing with duration and cumulative dose. The labeling provides explicit warnings and contraindications, but cases continue to arise, particularly with long-term use. Affected patients in Massachusetts should be aware of the time limits for filing claims and the importance of documenting the timeline of exposure and symptom onset.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Reglan Tardive Dyskinesia claims in Massachusetts?
In Massachusetts, the statute of limitations for personal injury claims, including those related to Reglan-induced Tardive Dyskinesia, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. However, specific circumstances may affect this timeline, so consulting with an attorney is essential.
How does the risk of Tardive Dyskinesia relate to Reglan use?
Reglan (metoclopramide) carries a boxed warning about the risk of Tardive Dyskinesia, a potentially irreversible movement disorder. The risk increases with longer treatment duration and higher cumulative doses. The FDA recommends using Reglan for no longer than 12 weeks for most indications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.